Kezar Life Sciences, Inc. KZR · Stock Open Kezar Life Sciences, Inc. in new tab
Kezar Life Sciences, Inc. Analysis (KZR)
Is Kezar Life Sciences, Inc. a good investment? Kezar Life Sciences, Inc. (KZR) is currently trading at 7.29 USD. Market analysts have a consensus price target of 6.00 USD. This suggests the asset is currently trading above analyst expectations.
Earnings Schedule: Kezar Life Sciences, Inc. is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -4.66.
Investor FAQ
Does Kezar Life Sciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Kezar Life Sciences, Inc.?
Kezar Life Sciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -6.17.
Company Profile
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 30, 2024 | 1:10 |
Community Discussion